tryn2 My statement is based on the situation we are in now, low share price in relation to the relatively low market cap.
I guess it mostly will depend on market cap. If share price is overly depressed as of it's today, the price will definitely overshoot when positive topline data are announced; on the other hand, if share price appreciates substantially with the waiting period up to topline data announcement, it may and may not have an overshoot, all depending on what market cap one would expect on what results of the topline data will be.
It's very hard or almost impossible to predict exactly how the price movement would be in general considering there are other myriad factors in play as well.
I recalled DNDN's share price crashed in a short period of time, I remembered in that morning when the company announced its confirmatory second p3 trial results, and the results are positive. I was stun seeing the positive results and the crashed share price, but believed it was a major short attack manipulation after some search in the Internet for potentially missed negative news, which was none.
So one would never know and the fact is that anything could happen. Nonetheless, one can certainly predict the general trend. In our case, if the trial results are what we expect, the share price would be heading in a course of major appreciation or correction, but the road ahead may not be as clear as we hope for. Regardless, the price will after a certain period of time correlate to a reasonable market cap.
So one should draw some lines of market cap expectations to weigh in on actions from time to time, either to add or unload some shares based on the changing situations and ones own risk tolerance level.
Just my two cents.
